Synthesis, Docking and Biological Activities of Novel Hybrids Celecoxib and Anthraquinone Analogs as Potent Cytotoxic Agents

被引:15
作者
Almutairi, Maha S. [1 ]
Hegazy, Gehan H. [2 ]
Haiba, Mogedda E. [1 ,6 ]
Ali, Hamed I. [3 ,4 ]
Khalifa, Nagy M. [5 ,6 ]
Soliman, Abd El-mohsen M. [6 ]
机构
[1] King Saud Univ, Fac Pharm, Dept Pharmaceut Chem, Riyadh 11451, Saudi Arabia
[2] Cairo Univ, Fac Pharm, Dept Pharmaceut Chem, Cairo 11562, Egypt
[3] Texas A&M Hlth Sci Ctr, Irma Lerma Rangel Coll Pharm, Dept Pharmaceut Sci, Kingsville, TX 78363 USA
[4] Helwan Univ, Fac Pharm, Dept Pharmaceut Chem, Cairo 11790, Egypt
[5] King Saud Univ, Coll Pharm, Dept Pharmaceut Chem, DEDC, Riyadh 11451, Saudi Arabia
[6] Natl Res Ctr, Dept Therapeut Chem, Pharmaceut & Drug Ind Div, Cairo 12622, Egypt
关键词
antitumor; anthraquinone; celecoxib; HEPG2; docking; protein kinase activities; SELECTIVE CYCLOOXYGENASE-2; ANTITUMOR-ACTIVITY; INHIBITION; ENHANCEMENT; DERIVATIVES; CARCINOMA; DESIGN;
D O I
10.3390/ijms151222580
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Herein, novel hybrid compounds of celecoxib and 2-aminoanthraquinone derivatives have been synthesized using condensation reactions of celecoxib with 2-aminoanthraquinone derivatives or 2-aminoanthraquinon with celecoxib derivatives. Celecoxib was reacted with different acid chlorides, 2-chloroethylisocyanate and bis (2-chloroethyl) amine hydrochloride. These intermediates were then reacted with 2-aminoanthraquinone. Also the same different acid chlorides and 2-chloroethylisocyanate were reacted with 2-aminoanthraquinone and the resulting intermediates were reacted with celecoxib to give isomers for the previous compounds. The antitumor activities against hepatic carcinoma tumor cell line (HEPG2) have been investigated in vitro, and all these compounds showed promising activities, especially compound 3c, 7, and 12. Flexible docking studies involving AutoDock 4.2 was investigated to identify the potential binding affinities and the mode of interaction of the hybrid compounds into two protein tyrosine kinases namely, SRC (Pp60v-src) and platelet-derived growth factor receptor, PDGFR (c-Kit). The compounds in this study have a preferential affinity for the c-Kit PDGFR PTK over the non-receptor tyrosine kinase SRC (Pp60v-src).
引用
收藏
页码:22580 / 22603
页数:24
相关论文
共 35 条
[1]  
Abo-Ghalia M H, 2000, Acta Pol Pharm, V57, P53
[2]   Structure-based drug design and AutoDock study of potential protein tyrosine kinase inhibitors [J].
Ali, Hamed Ismail ;
Nagamatsu, Tomofumi ;
Akaho, Eiichi .
BIOINFORMATION, 2011, 5 (09) :368-374
[3]  
Aragon-Ching B.J., 2009, UPDATE CANC THER, V3, P182
[4]  
Attoub S, 2002, CANCER RES, V62, P4879
[5]  
Bamba H, 2000, J EXP CLIN CANC RES, V19, P219
[6]  
BERGHOT MA, 1992, PHARMAZIE, V47, P340
[7]   Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck [J].
Choe, Mi Sun ;
Chen, Zhuo ;
Klass, Carmen M. ;
Zhang, Xin ;
Shin, Dong M. .
CLINICAL CANCER RESEARCH, 2007, 13 (10) :3015-3023
[8]   Antitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in Vitro and in Vivo [J].
Dai, Zhi-Jun ;
Ma, Xiao-Bin ;
Kang, Hua-Feng ;
Gao, Jie ;
Min, Wei-Li ;
Guan, Hai-Tao ;
Diao, Yan ;
Lu, Wang-Feng ;
Wang, Xi-Jing .
CANCER CELL INTERNATIONAL, 2012, 12
[9]  
DENNY WA, 1990, ANTI-CANCER DRUG DES, V5, P189
[10]  
Garde AH, 2000, CLIN CHEM, V46, P551